{"analyses":[{"ciLowerLimit":"0.707","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.369","estimateComment":"Hazard ratio (HR) was based on a stratified Cox's proportional hazard regression model with stratification factors: disease type, IPI Score and region with treatment as a factor in the model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.338","paramType":"Hazard Ratio (HR)","paramValue":"0.98","statisticalMethod":"Stratified Log-rank Test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"263","upperLimit":"514","value":"415"},{"groupId":"OG001","lowerLimit":"258","upperLimit":"572","value":"367"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death. Participants without documentation of death were censored at the date last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).","id":"OG000","title":"Alisertib"},{"description":"Pralatrexate 30 mg/m\\^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m\\^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m\\^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).","id":"OG001","title":"Pralatrexate, or Romidepsin, or Gemcitabine"}],"paramType":"MEDIAN","populationDescription":"ITT population was defined as all participants who were randomized. The participants were analyzed according to the treatment they were randomized to receive, regardless of any errors of dosing.","reportingStatus":"POSTED","timeFrame":"Participants were followed for survival for 2 years from date of last participant off study treatment, or death, whichever occurs first. Contacts were every 4 months (Median follow-up 519 days in the alisertib arm and 586 days in the comparative arm)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"days"}